As shown in Fig 1, I-FABP serum concentrations were significantly decreased in patients with COVID-19, as compared to control patients with non-COVID-19 pulmonary diseases [Med: 70.3 pg/mL (IQ: 47–167.9) vs. 161.1 pg/mL (IQ: 88.98–305.2), respectively, p = 0. This evidence concerns the gene FABP2 and COVID-19.